Unibest

Pharmaceutical intermediates

Elagolix Sodium Intermediates

5 pharmaceutical intermediates for Elagolix Sodium. Indication: Endometriosis, pain.

提交项目All intermediates

About Elagolix Sodium

Originator
Neurocrine Biosciences, Inc.
Indication
Endometriosis, pain
Approved Date
07/23/2018
DS/DP
07/06/2029

Available intermediates

5 intermediates currently listed for Elagolix Sodium. Request specifications, documentation or a quotation for any item below.

Elagolix Sodium intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
N-[(1R)-2-[(Methylsulfonyl)oxy]-1-phenylethyl]carbamic acid 1,1-dimethylethyl ester102089-75-8//
1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione830346-47-9//
5-Bromo-1-(2-fluoro-6-trifluoromethyl-benzyl)-6- methyl-1H-pyrimidine-2,4-dione830346-48-0//
1-[2-fluoro-6-(trifluoromethyl)benzyl]-5-iodo-6-methylpyrimidine-2,4(1H,3H)-dione1150560-54-5//
5-(2-Fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione1150560-59-0//

Other programs under E

Edoxaban tosylate monohydrateElacestrantEldecalcitolElinzanetantElobixibatEltrombopagEltrombopag OlamineEluxadoline

Building toward Elagolix Sodium?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →